^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    JNJ-63709178

    i
    Other names: JNJ-63709178, CD123 x CD3 DuoBody, JNJ 63709178, CD123-CD3 DuoBody protein, CNTO 9958, JNJ-9178
    Associations
    News

    Trials

    Company:
    Genmab, J&J
    Drug class:
    CD3 agonist, CD123 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) (NCT02715011)
    Phase 1
    Janssen Research & Development, LLC
    Completed
    Last update posted :
    08/31/2021
    Initiation :
    06/01/2016
    Primary completion :
    03/26/2021
    Completion :
    03/26/2021
    CD123 • IL3RA
    |
    CD123 expression • IL3RA expression
    |
    JNJ-63709178